AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25195923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed gFOBT kit and second mailed CRC screening invitation
Number of subjects: 3584
Study 25195923 — intervention group
Group type: COMPARATOR
Intervention: Second mailed CRC screening invitation alone
Number of subjects: 3584
Study 23092711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 23092711 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 0
Study 21816787 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 84
Study 21816787 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 84
Study 19796455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 3.5 mg and bicalutamide 50 mg once daily
Number of subjects: 0
Study 19796455 — intervention group
Group type: COMPARATOR
Intervention: Placebo and bicalutamide 50 mg once daily
Number of subjects: 0
Study 17003246 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic organizers
Number of subjects: 0
Study 17003246 — intervention group
Group type: COMPARATOR
Intervention: No graphic organizers (control group)
Number of subjects: 0
Study 12700715 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (CLZ)
Number of subjects: 160
Study 12700715 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ)
Number of subjects: 160
Study 11041569 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 44
Study 11041569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9153544 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 46
Study 9153544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8095008 — intervention group
Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy
Number of subjects: 0
Study 8095008 — intervention group
Group type: EXPERIMENTAL
Intervention: Later zidovudine therapy
Number of subjects: 0
Study 8095008 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked therapy continuation
Number of subjects: 0
Study 8095008 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmasked treatment and follow-up
Number of subjects: 0
Study 3680580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 50 mg
Number of subjects: 24
Study 3680580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 100 mg
Number of subjects: 24
Study 3680580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 200 mg
Number of subjects: 24
Study 3680580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 300 mg
Number of subjects: 24
Study 3680580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg q12h for 7 days
Number of subjects: 24
Study 3680580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30218012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP)
Number of subjects: 220
Study 30218012 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care (control)
Number of subjects: 220
Study 30218012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) with higher adherence
Number of subjects: 220
Study 27496186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponseti method
Number of subjects: 39
Study 27496186 — intervention group
Group type: COMPARATOR
Intervention: Early tibialis anterior tendon transfer (TATT)
Number of subjects: 39
Study 26509991 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-Lok implants (LL)
Number of subjects: 77
Study 26509991 — intervention group
Group type: COMPARATOR
Intervention: Non-Laser-Lok implants (NLL)
Number of subjects: 77
Study 23398493 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive behavioral therapy (CBT)
Number of subjects: 76
Study 23398493 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 76
Study 23398493 — intervention group
Group type: COMPARATOR
Intervention: Self-control desensitization
Number of subjects: 76
Study 22026413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular ropivacaine infusion (0.5%, 2 mL/h)
Number of subjects: 36
Study 22026413 — intervention group
Group type: COMPARATOR
Intervention: Extraarticular ropivacaine infusion (0.5%, 2 mL/h)
Number of subjects: 36
Study 18836357 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lumbar disc replacement
Number of subjects: 20
Study 18836357 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level lumbar transforaminal interbody fusion (TLIF)
Number of subjects: 20
Study 18836357 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior spinal fusion (ASF)
Number of subjects: 20
Study 18836357 — intervention group
Group type: COMPARATOR
Intervention: Anterior and posterior spinal fusion (ASF/PSF)
Number of subjects: 20
Study 17297828 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 1 mL of saline (Group II)
Number of subjects: 60
Study 17297828 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 150 microg of clonidine (Group IV)
Number of subjects: 60
Study 17297828 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 1% mepivacaine with 150 microg of clonidine plus 4mL of saline (Group III)
Number of subjects: 60
Study 17297828 — intervention group
Group type: COMPARATOR
Intervention: 40 mL of 1% mepivacaine with adrenaline plus 5 mL of saline (Group I - Control)
Number of subjects: 60
Study 14520605 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (2 mg)
Number of subjects: 20
Study 14520605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11119051 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as add-on therapy
Number of subjects: 237
Study 11119051 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) in patients with central area epilepsies
Number of subjects: 237
Study 9207646 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution fractal dimension (D)
Number of subjects: 484
Study 9207646 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution fractal dimension (D) in randomized patient group
Number of subjects: 484
Study 7982347 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual forms of pulmonary embolism
Number of subjects: 0
Study 2586439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy (CDDP+VDS, IL2+LAK cells)
Number of subjects: 0
Study 2586439 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro stimulated LAK cells (St-LAK) administered locally
Number of subjects: 0
Study 2586439 — intervention group
Group type: EXPERIMENTAL
Intervention: LAK-BAI (bronchial arterial infusion) combined with radiation therapy
Number of subjects: 0
Study 2586439 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CDDP + VDS)
Number of subjects: 0
Study 2586439 — intervention group
Group type: COMPARATOR
Intervention: Control group A
Number of subjects: 0
Study 1135876 — intervention group
Group type: EXPERIMENTAL
Intervention: pHisohex
Number of subjects: 36
Study 1135876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperphaze
Number of subjects: 36
Study 1135876 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study 31475938 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular mobilization (Group 1, n=27)
Number of subjects: 54
Study 31475938 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual posterior capsule stretching (Group 2, n=27)
Number of subjects: 54
Study 31475938 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined application of scapular mobilization and manual posterior capsule stretching (n=54)
Number of subjects: 54
Study 31475938 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 54
Study 29214925 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO + EXE (100 mg of isoflavone and exercise)
Number of subjects: 32
Study 29214925 — intervention group
Group type: COMPARATOR
Intervention: PLA + EXE (placebo and exercise)
Number of subjects: 32
Study 25994188 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection loading (100 ml 5% glucose injection + 50 ml Shenfu injection)
Number of subjects: 160
Study 25994188 — intervention group
Group type: COMPARATOR
Intervention: Control group (150 ml 5% glucose injection)
Number of subjects: 160
Study 24952857 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP-guided treatment
Number of subjects: 340
Study 24952857 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 340
Study 22547382 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate coated (HA) cups
Number of subjects: 8
Study 22547382 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous-coated (PC) cups
Number of subjects: 8
Study 22547382 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy hip (reference group)
Number of subjects: 8
Study 19282610 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 92
Study 17890496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 64
Study 17890496 — intervention group
Group type: COMPARATOR
Intervention: NCEP diet (control)
Number of subjects: 64
Study 17890496 — intervention group
Group type: EXPERIMENTAL
Intervention: Group support
Number of subjects: 64
Study 17890496 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting attendance
Number of subjects: 64
Study 15165413 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological coherence condition
Number of subjects: 26
Study 15165413 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition of 'normal' psychophysiologic function
Number of subjects: 26
Study 11943102 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 1911
Study 11943102 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no effect on H. pylori infection)
Number of subjects: 1911
Study 9649995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.9 mg kg‐1)
Number of subjects: 30
Study 9649995 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.12 mg kg‐1)
Number of subjects: 30
Study 8543493 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 h (n = 77)
Number of subjects: 160
Study 8543493 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2 g and metronidazole 500 mg every 8 h (n = 83)
Number of subjects: 160
Study 2382949 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 30
Study 2382949 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 30
Study 2382949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 30
Study 6797288 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso‐jejunal feedings (group I)
Number of subjects: 17
Study 6797288 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (group II)
Number of subjects: 17
Study 31922355 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission risk index (RI)
Number of subjects: 0
Study 31039754 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of an individually tailored, progressive home exercise program and physical activity promotion delivered by professional instructors and lay instructors (two home visits per week) and long-term care counselling
Number of subjects: 240
Study 31039754 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 31039754 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 240
Study 29153415 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (FOM) DPI (9 μg via a Turbuhaler®)
Number of subjects: 52
Study 29153415 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium bromide (TIO) DPI (18μg via a HandiHaler®)
Number of subjects: 52
Study 25986615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1×10^8 CFU for five days) + Oral Rehydration Solution (ORS)
Number of subjects: 64
Study 25986615 — intervention group
Group type: COMPARATOR
Intervention: Control group (ORS only)
Number of subjects: 64
Study 25986615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 + ORS
Number of subjects: 64
Study 23166147 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-based anaesthesia
Number of subjects: 100
Study 23166147 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-based anaesthesia
Number of subjects: 100
Study 21739290 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-based HIV sexual risk reduction intervention
Number of subjects: 166
Study 21739290 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-based HIV sexual risk reduction intervention plus motivational interviewing
Number of subjects: 166
Study 21739290 — intervention group
Group type: COMPARATOR
Intervention: Control condition focused on wellness promotion
Number of subjects: 166
Study 18754021 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h blood pressure management strategy (target <130/80 mm Hg)
Number of subjects: 136
Study 18754021 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy using office BP (target <140/90 mm Hg)
Number of subjects: 136
Study 18754021 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h blood pressure management strategy
Number of subjects: 136
Study 18754021 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy using office BP
Number of subjects: 136
Study 16998260 — intervention group
Group type: EXPERIMENTAL
Intervention: PercuSurge GuardWire System
Number of subjects: 58
Study 16998260 — intervention group
Group type: COMPARATOR
Intervention: No distal protection device
Number of subjects: 58
Study 15769682 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 732
Study 15769682 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG)
Number of subjects: 732
Study 15769682 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 732
Study 15769682 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 732
Study 15769682 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB patients with moderate LVD
Number of subjects: 732
Study 15769682 — intervention group
Group type: COMPARATOR
Intervention: CABG and OPCAB patients with severe LVD
Number of subjects: 732
Study 10953942 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict resolution training integrated into a curriculum unit on friendship (9 hr over 4 weeks)
Number of subjects: 80
Study 10953942 — intervention group
Group type: COMPARATOR
Intervention: Control condition (identical friendship unit without conflict resolution training)
Number of subjects: 80
Study 1818806 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 60
Study 1818806 — intervention group
Group type: COMPARATOR
Intervention: Gamma-OH
Number of subjects: 60
Study 6651994 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 585
Study 6651994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study 6651994 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (subsample of 171 patients)
Number of subjects: 585
Study 29941406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide
Number of subjects: 0
Study 29941406 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir plus abacavir and lamivudine
Number of subjects: 0
Study 27262254 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0
Study 27262254 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study 24752322 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC group (propofol infusion via a 1‐m PVC infusion extension tube)
Number of subjects: 100
Study 24752322 — intervention group
Group type: COMPARATOR
Intervention: Control group (propofol injected directly through the port of the cannula)
Number of subjects: 100
Study 24752322 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC group
Number of subjects: 100
Study 24752322 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 24752322 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (di(2‐ethylhexyl) phthalate added to samples)
Number of subjects: 100
Study 22261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Four treatment regimens for NGU
Number of subjects: 305
Study 22261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of education
Number of subjects: 305
Study 22261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical centers with higher monetary incentives
Number of subjects: 305
Study 19874436 — intervention group
Group type: COMPARATOR
Intervention: Device eligibility based on MADIT-II criteria
Number of subjects: 4977
Study 19874436 — intervention group
Group type: COMPARATOR
Intervention: Device eligibility based on CARE-HF criteria
Number of subjects: 4977
Study 19874436 — intervention group
Group type: COMPARATOR
Intervention: Device eligibility based on SCD-HeFT criteria
Number of subjects: 4977
Study 19874436 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry patients with different trial-profile combinations
Number of subjects: 4977
Study 18506317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg), plus dexmedetomidine, 1 mg x kg‐1
Number of subjects: 40
Study 18506317 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg)
Number of subjects: 40
Study 16020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 39
Study 16020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 39
Study 16020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 39
Study 12356613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation with or without heat
Number of subjects: 336
Study 12356613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation with or without electrical muscle stimulation
Number of subjects: 336
Study 12356613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine mobilization with or without heat
Number of subjects: 336
Study 12356613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine mobilization with or without electrical muscle stimulation
Number of subjects: 336
Study 10474015 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 19
Study 8757002 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide (2.5 mg daily)
Number of subjects: 30
Study 8757002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1839061 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-ground sorghum cereal
Number of subjects: 10
Study 1839061 — intervention group
Group type: COMPARATOR
Intervention: Decorticated sorghum cereal
Number of subjects: 10
Study 6148905 — intervention group
Group type: EXPERIMENTAL
Intervention: Org NC 45 during neurolept anaesthesia
Number of subjects: 3
Study 6148905 — intervention group
Group type: EXPERIMENTAL
Intervention: Org NC 45 during enflurane anaesthesia
Number of subjects: 3
Study 6148905 — intervention group
Group type: EXPERIMENTAL
Intervention: Org NC 45 during halothane anaesthesia
Number of subjects: 3
Study 31392528 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 56 years and no lymphovascular invasion (LVI)
Number of subjects: 12918
Study 31392528 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients (age > 75 years) with melanoma 1.2 mm or smaller and no LVI
Number of subjects: 12918
Study 29478794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid test from finger-stick whole blood
Number of subjects: 270
Study 29478794 — intervention group
Group type: COMPARATOR
Intervention: ELISA tests
Number of subjects: 270
Study 27614896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 18
Study 27614896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23617228 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 310
Study 23617228 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH)
Number of subjects: 310
Study 23402957 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation with Extension subgroup
Number of subjects: 41
Study 23402957 — intervention group
Group type: COMPARATOR
Intervention: Control group (without low back pain)
Number of subjects: 41
Study 23402957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 21409494 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan (20 mg single dose)
Number of subjects: 10
Study 21409494 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study 18079302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 40
Study 16782422 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (750 mg), Vitamin K1 (1.0 mg), Vitamin D3 (10.0 microg)
Number of subjects: 40
Study 16782422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14668280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-bioavailability diet (13.1 mg/d nonheme iron, 2.0 mg/d heme iron)
Number of subjects: 0
Study 14668280 — intervention group
Group type: COMPARATOR
Intervention: Low-bioavailability diet (14.8 mg/d nonheme iron, 0.3 mg/d heme iron)
Number of subjects: 0
Study 10751219 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 meq NaCl/day
Number of subjects: 32
Study 10751219 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 meq NaCl/day
Number of subjects: 32
Study 10751219 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 meq NaCl/day
Number of subjects: 32
Study 10751219 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 meq NaCl/day
Number of subjects: 32
Study 8667198 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 microgram)
Number of subjects: 8